Abstract
One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 389-397 |
| Number of pages | 9 |
| Journal | Nature Reviews Cancer |
| Volume | 7 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2007 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Insights from transgenic mouse models of ERBB2-induced breast cancer. / Ursini-Siegel, Josie; Schade, Babette; Cardiff, Robert; Muller, William J.
In: Nature Reviews Cancer, Vol. 7, No. 5, 01.05.2007, p. 389-397.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Insights from transgenic mouse models of ERBB2-induced breast cancer
AU - Ursini-Siegel, Josie
AU - Schade, Babette
AU - Cardiff, Robert
AU - Muller, William J.
PY - 2007/5/1
Y1 - 2007/5/1
N2 - One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.
AB - One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.
UR - http://www.scopus.com/inward/record.url?scp=34247499539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247499539&partnerID=8YFLogxK
U2 - 10.1038/nrc2127
DO - 10.1038/nrc2127
M3 - Review article
C2 - 17446858
AN - SCOPUS:34247499539
VL - 7
SP - 389
EP - 397
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
SN - 1474-175X
IS - 5
ER -